Thyrocare Technologies liquidity ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
32.07×————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
3.39×3.39×2.77×3.08×3.54×
2.95×2.95×2.39×2.55×3.18×
164190155146140
266262216188196
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

THYROCARE₹515.50

Thyrocare Technologies Ltd.

· Pharma & Health
₹ CrorePeersLALPATHLABMETROPOLISVIJAYASUPRIYAVIYASHSTARSPARCYATHARTHMcap ₹8,205 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Altman Z-Score (Other Equity as RE)————32.07
Current Ratio3.543.082.773.393.39
Quick Ratio3.182.552.392.952.95
Cash, Equiv & ST Investments140.1146.1155.0189.8163.6
Working Capital195.8188.0215.9262.4266.0
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.